Diabetes Care;肾病增高糖尿病视网膜病变风险

2013-01-04 Diabetes Care CMT 晓东 编译

     非增生性糖尿病视网膜病和视网膜出血       增生性糖尿病视网膜病和新血管    2012年12月28日在线发表于《糖尿病护理》的一项研究表明,血糖控制、眼部以外并发症(肾病、未愈合溃疡)与糖尿病视网膜病变风险增高相关。视网膜病变进展风险评分可帮助临床医生对糖尿病眼底病变高风险患者进行分层。   该研究为一项回顾性队列研究,旨在对非增生性视网膜病变(NPD

  糖尿病视网膜病变非增生

  非增生性糖尿病视网膜病和视网膜出血 

  增生性糖尿病视网膜病变

  增生性糖尿病视网膜病和新血管 

  2012年12月28日在线发表于《糖尿病护理》的一项研究表明,血糖控制、眼部以外并发症(肾病、未愈合溃疡)与糖尿病视网膜病变风险增高相关。视网膜病变进展风险评分可帮助临床医生对糖尿病眼底病变高风险患者进行分层。

  该研究为一项回顾性队列研究,旨在对非增生性视网膜病变(NPDR)进展为增生性视网膜病变(PDR)的相关危险因素进行鉴别。

  研究者在2001-2009年纳入到大型医疗管理网络、年龄≥30岁的眼部疾病患者中选取索赔数据库中的资料,对新诊断NPDR患者进行纵向随访。采用多变量回归分析鉴别NPDR进展为PDR的危险因素,确定3年与5年视网膜病变进展概率。

  研究共纳入4617名入NPDR患者,其中307例(6.6%)患者进展为PDR。经混杂校正,HbA1c每升高一个百分点,进展为PDR的风险上升14%(经校正危害比1.14 [95%可信区间1.07–1.21])。存在未愈合溃疡的患者进展为PDR的风险增加了54%,合并肾病的患者进展为PDR的风险显著增加。低危患者5年预估NPDR进展发生率为5%,高危患者则为38%。

  研究者提示,在糖尿病患者中鉴别那些进展为糖尿病视网膜病变的高危患者,并通过早期干预措施,可将其视力损失降低到最低。

  非增生性糖尿病视网膜病 (non-proliferative diabetic retinopathy):特征为血管膨胀、微动脉瘤(血管变弱)、视网膜出血,以及视网膜浮肿。增生性糖尿病视网膜病 (proliferative diabetic retinopathy) :特征为新血管形成。  

视网膜病变相关的拓展阅读:


Predicting Development of Proliferative Diabetic Retinopathy

OBJECTIVE 

Identifying individuals most at risk for diabetic retinopathy progression and intervening early can limit vision loss and reduce the costs associated with managing more advanced disease. The purpose of this study was to identify factors associated with progression from nonproliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR).

RESEARCH DESIGN AND METHODS 

This was a retrospective cohort analysis using a claims database of all eye care recipients age ≥30 years enrolled in a large managed-care network from 2001 to 2009. Individuals with newly diagnosed NPDR were followed longitudinally. Multivariable Cox regression analyses identified factors associated with progression to PDR. Three- and five-year probabilities of retinopathy progression were determined.

RESULTS 

Among the 4,617 enrollees with incident NPDR, 307 (6.6%) developed PDR. After adjustment for confounders, every 1-point increase in HbA1c was associated with a 14% (adjusted hazard ratio 1.14 [95% CI 1.07–1.21]) increased hazard of developing PDR. Those with nonhealing ulcers had a 54% (1.54 [1.15–2.07]) increased hazard of progressing to PDR, and enrollees with nephropathy had a marginally significant increased hazard of progressing to PDR (1.29 [0.99–1.67]) relative to those without these conditions. The 5-year probability of progression for low-risk individuals with NPDR was 5% (range 2–8) and for high-risk patients was 38% (14–55).

CONCLUSIONS 

Along with glycemic control, nonophthalmologic manifestations of diabetes mellitus (e.g., nephropathy and nonhealing ulcers) are associated with an increased risk of diabetic retinopathy progression. Our retinopathy progression risk score can help clinicians stratify patients who are most at risk for disease progression.



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901042, encodeId=5ade19010426a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Feb 09 10:03:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759235, encodeId=445c1e59235eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 19 03:03:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636615, encodeId=5138163661588, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 17 03:03:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269776, encodeId=4fec1269e761f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413855, encodeId=58781413855af, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561540, encodeId=20e3156154064, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567549, encodeId=b3ae156e549aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1901042, encodeId=5ade19010426a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Feb 09 10:03:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759235, encodeId=445c1e59235eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 19 03:03:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636615, encodeId=5138163661588, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 17 03:03:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269776, encodeId=4fec1269e761f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413855, encodeId=58781413855af, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561540, encodeId=20e3156154064, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567549, encodeId=b3ae156e549aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1901042, encodeId=5ade19010426a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Feb 09 10:03:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759235, encodeId=445c1e59235eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 19 03:03:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636615, encodeId=5138163661588, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 17 03:03:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269776, encodeId=4fec1269e761f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413855, encodeId=58781413855af, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561540, encodeId=20e3156154064, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567549, encodeId=b3ae156e549aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1901042, encodeId=5ade19010426a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Feb 09 10:03:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759235, encodeId=445c1e59235eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 19 03:03:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636615, encodeId=5138163661588, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 17 03:03:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269776, encodeId=4fec1269e761f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413855, encodeId=58781413855af, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561540, encodeId=20e3156154064, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567549, encodeId=b3ae156e549aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
    2013-01-06 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1901042, encodeId=5ade19010426a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Feb 09 10:03:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759235, encodeId=445c1e59235eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 19 03:03:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636615, encodeId=5138163661588, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 17 03:03:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269776, encodeId=4fec1269e761f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413855, encodeId=58781413855af, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561540, encodeId=20e3156154064, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567549, encodeId=b3ae156e549aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1901042, encodeId=5ade19010426a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Feb 09 10:03:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759235, encodeId=445c1e59235eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 19 03:03:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636615, encodeId=5138163661588, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 17 03:03:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269776, encodeId=4fec1269e761f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413855, encodeId=58781413855af, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561540, encodeId=20e3156154064, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567549, encodeId=b3ae156e549aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
    2013-01-06 liuxiaona
  7. [GetPortalCommentsPageByObjectIdResponse(id=1901042, encodeId=5ade19010426a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Sat Feb 09 10:03:00 CST 2013, time=2013-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759235, encodeId=445c1e59235eb, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Mar 19 03:03:00 CST 2013, time=2013-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636615, encodeId=5138163661588, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 17 03:03:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269776, encodeId=4fec1269e761f, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413855, encodeId=58781413855af, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561540, encodeId=20e3156154064, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567549, encodeId=b3ae156e549aa, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sun Jan 06 01:03:00 CST 2013, time=2013-01-06, status=1, ipAttribution=)]
    2013-01-06 liuxiaona

相关资讯

Diabetes:软脂酸/油酸比例与女性糖尿病发病风险呈正相关

相对于富含软脂酸(PA)的食物,富含油酸(OA)的食物与降低2型糖尿病风险相关,但具体机制不明。为此,美国佛蒙特大学研究者Kien CL在年轻人中开展了一项饮食中脂质组学与胰岛素敏感性关系的研究(A Lipidomics Analysis of the Relationship Between Dietary Fatty Acid Composition and Insulin Sensitivi

Thorax:糖尿病患者肺结核防治形势严峻

  墨西哥一项前瞻性研究发现,随着全球糖尿病患病率的增加,有必要对这些糖尿病患者进行肺结核(TB)的预防和管理及评估相应的效应。同时患有两种病的患者有全球蔓延的潜在危险,提示TB管理的重要性。相关论文12月18日在线发表于《胸腔》(Thorax)杂志。   研究纳入了南墨西哥于1995年至2010年通过对痰标本进行流行病学、临床微生物学评估而确诊的TB患者,每年随访一次,以确定治疗转归、有

Diabetes Care:二甲双胍能改善心血管高危的2型糖尿病患者心血管预后(SPREAD-DIMCAD研究

  12月10日,3项中国研究同时亮相《糖尿病护理》(Diabetes Care)杂志,让我们在品味研究结果的同时不禁为中国研究者喝彩。   上海交通大学医学院附属瑞金医院宁光教授牵头的)组糖化血红蛋白(HbA1c)均明显降低。中位随访5年时,91例发生103次主要终点事件(心血管死亡、全因死亡、非致死性心肌梗死、非致死性卒中和冠脉血运重建)。意向治疗分析显示,与格列吡嗪相比,二甲双胍

PLoS One:联合生长因子抑制剂可减少糖尿病小鼠的视力损害

Figure 2. Intravitreal injection of betacellulin induces increased retinal haemorrhage and augmented retinal vascular permeability in normal and diabetic retinas. 12月17日旧金山,ClevelandClinic研究人员BelaA

BMC Cancer:糖尿病恶化乳腺癌患者预后

  《生物医学中心癌症》(BMC Cancer)杂志2012年12月26日在线发表的一项研究指出,既往未诊断出糖尿病的老年乳腺癌患者,其临床分期和死亡率更高。   该研究是一项基于Seer-medicare数据库的观察性队列研究。研究者利用来自Surveillance、Epidemiology和End Results-Medicare linked dat

Diabetes:尿蛋白质组学可用于早期诊断糖尿病肾病

糖尿病肾病(DN)是一种逐渐进展的肾脏疾病,由长期高血糖引起的糖尿病的重要并发症。在西方国家,糖尿病肾病是透析的最常见原因。早期发现糖尿病肾病或许能运用药物进行干预治疗,从而延迟或避免使用肾脏替代治疗。为此,德国研究者Zürbig P进行了一项关于运用尿蛋白质组学诊断糖尿病肾病的研究(Urinary Proteomics for Early Diagnosis in Diabetic Nephro